4TEEN4 Pharmaceuticals provides biomarkers for diagnosis, prediction, and monitoring of acute medical conditions. It develops Procizumab, a humanized antibody targeting human dipeptidyl peptidase 3 (DPP3) for the treatment of acute cardiovascular diseases.